Ibogaine side effects

Discussion of ibogaine safety concentrates almost entirely on the cardiac risk, for good reason, with the result that the ordinary side effects get little attention. Those effects are not minor. In one closely monitored series every single patient was temporarily unable to walk unaided, and insomnia lasting around three days is a standard feature rather than an occasional complication.

Knowing what to expect matters for two reasons. It affects what a treatment setting has to be able to handle, since a person who cannot stand needs assistance for everything. And it affects practical planning, because effects that persist for days after the acute experience determine when someone can reasonably travel or return to normal activity.

The overall picture

Across the published studies the same effects recur: loss of coordination, nausea and vomiting, tremor, prolonged insomnia, and changes in blood pressure and heart rate, alongside the QT prolongation that dominates the safety literature. The 191-person inpatient series in St Kitts recorded nausea, vomiting and gait ataxia as the most common side effects, with orthostatic hypotension in 5 percent of participants, and reported no serious adverse events and no deaths in that series [2].

Most of these effects are transient, which is not the same as trivial. They are also predictable enough that their management is a basic test of whether a setting is equipped for the treatment it is offering.

One structural caveat applies to all of the figures below. Side effect rates come from studies with careful screening and exclusions, which means they describe what happens to people selected as suitable for treatment. A population that had not been screened for cardiac, liver and kidney problems, electrolyte abnormality and interacting medication would not be expected to produce the same numbers, and in the one direction that matters.

Loss of coordination

Ataxia is the most consistently reported physical effect and the most underdescribed. In a Dutch study of 14 patients given a single 10 milligram per kilogram dose, severe transient ataxia leaving participants unable to walk unaided affected all 14 [1]. Not most of them, and not the majority: all of them.

The companion pharmacokinetic analysis measured ataxia formally with a standardised rating scale and found it tracked ibogaine concentrations rather than noribogaine concentrations [3]. That links the severity directly to how much of the parent compound is in circulation, which in turn depends on how quickly the person clears it, with CYP2D6 genotype driving a more than tenfold spread in clearance [3].

The underlying cause is an effect on the cerebellum, the structure coordinating movement and balance. The analog literature makes the point indirectly: 18-MC was developed partly because it lacks ibogaine's cerebellar neurotoxicity [6], which is a statement about ibogaine as much as about the analog.

Practically, this means a person under the influence of a treatment dose cannot safely walk to a bathroom, stand up, or manage themselves in any way for a period of hours. Any setting must assume total physical dependence for the duration, and a person attempting this alone would be unable to reach help.

There is a secondary consequence worth noting. Because ataxia is measurable and tracks drug concentration, it functions as a rough visible indicator of exposure. A person who is markedly more affected than expected is likely to be clearing the drug slowly, which also implies greater cardiac exposure. That observation does not substitute for an electrocardiogram, but it is one reason staff familiar with the treatment watch coordination closely rather than treating it as an inconvenience to be managed.

Nausea and vomiting

Nausea and vomiting were the most commonly reported side effects in the St Kitts series [2] and are a standard feature of the experience rather than an adverse reaction in the usual sense.

The complication is that vomiting interacts with the cardiac risk. Fluid and electrolyte loss lowers potassium and magnesium, and both independently affect cardiac repolarisation and arrhythmia risk. The Dutch protocol required potassium between 3.5 and 5.0 millimoles per litre before dosing [1], and documented clinic practice includes intravenous fluids and electrolytes for this reason.

There is a further problem specific to an oral drug. Vomiting after a dose raises the question of how much was absorbed, and the answer cannot be determined without blood sampling. That introduces uncertainty about exposure in exactly the direction that makes dosing decisions difficult.

Tremor

Tremor is documented and is specific to ibogaine rather than its metabolite. In rats given intravenous ibogaine or noribogaine, ibogaine produced dose-related tremor and noribogaine did not [7]. The analog literature again supports this by contrast, noting that 18-MC lacks the tremor ibogaine produces [6].

That ibogaine causes tremor while noribogaine does not reinforces a pattern running through its side effect profile. The unpleasant physical effects track the parent compound, which is also what the cardiac and ataxia data showed [3]. A slow metaboliser therefore experiences more of all of them.

Insomnia and exhaustion

The effect that most often surprises people is the insomnia, because it comes after the experience is over and lasts much longer than expected. A retrospective case series of 33 heroin-dependent people describes insomnia often lasting 72 hours, responsive to sleep medication [4].

Three days without meaningful sleep is physiologically significant on its own, and it arrives on top of recent drug withdrawal and an intense psychological experience. It affects mood, judgement and the capacity to engage with anything therapeutic, and it is one reason monitoring periods extending to 72 hours, as used for the veteran cohort [8], make sense for reasons beyond the cardiac.

Planning follows from this. Someone expecting to travel the day after dosing is planning around an experience that does not end when the acute effects do.

The insomnia also has a bearing on how the aftermath is interpreted. Three days of sleeplessness produces low mood, irritability and poor concentration in anyone, and those are the same features someone might read as the treatment having failed or as depression returning. Distinguishing the predictable consequence of not sleeping from a genuine change in condition is difficult in the first week, which is an argument for not drawing firm conclusions during it.

Blood pressure and heart rate

Orthostatic hypotension, a drop in blood pressure on standing, occurred in 5 percent of the St Kitts participants [2]. Combined with ataxia, that compounds the fall risk considerably, since a person who is both unsteady and liable to faint on standing should not be attempting to stand.

Heart rate matters in screening as well as during treatment. The St Kitts series excluded anyone with a resting heart rate below 50 beats per minute [2], because a slow baseline rate itself contributes to the conditions in which QT-related arrhythmias occur.

The cardiac effect in context

The cardiac effect belongs in any side effect list, though it is categorically different from the others because it is the one that can be fatal. In the Dutch series, maximum QT prolongation averaged 95 milliseconds with a range from 29 to 146, 7 of 14 patients passed 500 milliseconds, and in 6 of 14 an interval above 450 milliseconds persisted beyond 24 hours. No torsades de pointes occurred in that group [1].

The mechanism is block of the hERG potassium channel in heart muscle, and the review of ibogaine's cardiac pharmacology notes that the QT prolongation outlasts the presence of ibogaine in the blood [5]. Unlike the other effects on this list, this one is invisible without an electrocardiogram, which is why monitoring rather than observation is the requirement.

Worth stating plainly is that the absence of serious adverse events in a given series does not generalise. The St Kitts report of no serious adverse events and no deaths covers 191 people screened by physical examination, safety laboratory tests and a 12-lead electrocardiogram, with telemetry from an hour before dosing to 24 hours after [2]. It is a statement about what happened under those conditions, in that number of people, and not a general safety figure.

Psychological effects and what is unverified

The acute psychological effects are the intended ones: closed-eye visual imagery and vivid recall of past events, described in the Dutch series, where one participant reported visual hallucinations. Formal delirium scores in that study stayed below threshold throughout [1], which indicates that the state, however intense, was not a confusional one by clinical measure.

One item deserves explicit flagging as unverified. The authors of the Dutch study note that the literature and internet forums suggest longer-lasting disturbing behavioural changes can occur after ibogaine, while stating that this was not observed or verified in their own cohort [1]. That is an acknowledged uncertainty rather than a finding, and it is recorded here because a possible effect that researchers themselves raise should not be omitted simply because it lacks confirmation.

How long effects last

The sequence from the case series runs roughly as follows. Intense effects begin one to three hours after ingestion and last about four to eight hours, with largely visual recall of past events. A second state of about 8 to 20 hours follows, with fewer images and attention turned to evaluating the recalled material, in a neutral, reflective tone. Insomnia then often continues for about 72 hours [4].

The physical effects broadly track that timeline, with ataxia and nausea concentrated in the acute phase and fatigue and insomnia dominating afterwards. The cardiac abnormality is the exception, since it can persist past 24 hours in a substantial minority [1], and it is the reason the end of the subjective experience is not the end of the risk period.

Two practical implications follow from that timeline. The treatment occupies a minimum of three days of total incapacity rather than a single day, which is a different proposition from how it is sometimes described. And the recovery period is not passive waiting: it is the stretch in which electrolytes are corrected, sleep is eventually re-established and the cardiac interval returns to baseline, all of which are reasons for someone medically qualified to remain involved rather than for the person to be discharged once they can stand.

Frequently asked questions

Will someone be able to walk during treatment?

Generally not. Severe transient ataxia leaving patients unable to walk unaided affected all 14 participants in one monitored series [1], and gait ataxia was among the most common effects in a 191-person series [2].

Is vomiting expected?

Yes. Nausea and vomiting were the most common side effects reported in the largest case series [2], and the resulting electrolyte loss matters because potassium and magnesium affect arrhythmia risk [1].

How long does the insomnia last?

Often around 72 hours, and it responds to sleep medication [4]. It arrives after the acute experience has ended.

Can someone travel the next day?

The published timeline argues against it. Insomnia often continues for about 72 hours [4], and in a screened cohort a prolonged QT interval persisted beyond 24 hours in 6 of 14 patients [1]. The veteran cohort was monitored for 72 hours [8].

Why are side effects worse for some people?

Largely because of clearance. Ataxia and QT prolongation both tracked ibogaine concentrations rather than noribogaine concentrations, and CYP2D6 genotype drove a more than tenfold spread in clearance [3].